[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-head-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-head-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100635003","superior-mesenteric-artery-first-versus-standard-approach-in-pancreaticoduodenectomy-100635003",false,"NCT07547033","Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy","EQUINOXE","Inclusion Criteria:\n\n1. Primary resectable or borderline with isolated veinous contact pancreatic adenocarcinoma (according to the NCCN classification and international consensual definition of Isaji 2018): resectability is evaluated on arterial-phase and portal-phase IV contrast-enhanced multislice CT scan of the pancreas (slice thickness: 2.5 mm), and assessed in a multidisciplinary staff meeting including at least one radiologist and one expert surgeon.\n2. CT-scan of the thorax and abdomen confirming non-metastatic PAC at least 45 days before inclusion\n3. MRI of the liver without metastasis performed maximum one month before inclusion\n4. CA 19.9 (carbohydrate antigen) level ≤ 500 U\u002FmL at the time of inclusion (in absence of cholestasis or biliary drainage)\n5. Age 18 or over\n6. Grade 0 or 1 Performans Status (ECOG)\n7. Normal renal and liver function at the time of inclusion (According to Cockroft and Gault's equation Glomerular Function Rate \\> 50ml\u002Fmin\u002Fm2; Prothrombin Time \\> 70%)\n8. Absolute neutrophil count \\> 1,500\u002Fmm3, platelet count \\> 100,000\u002Fmm3, haemoglobin level \\> 10 g\u002Fdl (transfusions are authorized) at time of inclusion\n9. Adequate contraception on fertile women\n10. \"Women of childbearing potential (defined as under 50 years of age and without a history of hysterectomy or tubal ligation) must not self-report being pregnant on the day of inclusion.\"\n11. Patient who provides a signed written informed consent form\n12. Patient having the rights to French social insurance\n\nExclusion Criteria:\n\n1. Pancreatic adenocarcinoma defined as \"borderline\" with arterial contact, locally advanced, non-resectable, or metastatic.\n2. Surgical or anesthesiologic contra-indications:\n\n   Non-controlled congestive heart failure - non-treated angina - recent myocardial infarction (in the previous year) - non-controlled AHT (SBP \\>160 mm or DBP \\> 100 mm, despite optimal drug treatment), long QT\n3. Major non-controlled infection\n4. Major comorbidity that may preclude the surgery\n5. Severe liver failure\n6. Any medical, psychological, or social situation that (in the investigator's opinion) could limit (i) the patient's compliance with the protocol or (ii) the ability to obtain or interpret data\n7. Pregnant or breastfeeding women and women of childbearing age not using effective means of contraception\n8. Curatorship or guardianship or patient placed under judicial protection\n9. Participation in other interventional research type 1, clinical investigation or clinical trial during the study\n\nSecondary exclusion criterion (during surgery):\n\n1. Evaluation of abdominal cavity, presenting infra-radiologic metastasis\n2. Positive tumoral invasion at frozen section after picking on the inter-aortic lymph nodes performed before any irrevocable organ section.\n3. Anasthaesiologic complication (induction allergy or unprevisible heart disease at induction)\n4. For fertile women: serological pregnancy test positive before surgery","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","\"Pancreatic cancer, especially pancreatic ductal adenocarcinoma, is one of the most serious and deadly cancers. Its outlook is very poor, with fewer than 10% of patients surviving five years after diagnosis. This is largely because the disease is often discovered at a late stage and because it frequently comes back even after surgery.\n\nWhen the tumor is located in the head of the pancreas, the only treatment that can potentially cure the disease is a major operation called a pancreaticoduodenectomy, also known as the Whipple procedure. This surgery is now safely performed in specialized hospitals, but it remains complex and carries a high risk of complications. Importantly, even after surgery, cancer cells often remain, leading to a high rate of local recurrence.\n\nA newer surgical technique, known as the \"artery-first\" approach, changes the order of the operation. By carefully exposing a major blood vessel near the pancreas at the beginning of the surgery, surgeons can better assess whether the tumor can be completely removed and can improve the precision of the operation.\n\nThis research protocol aims to compare this artery-first technique with the standard surgical approach. The goal is to determine whether starting the operation by addressing the artery allows for more complete tumor removal and reduces the risk of cancer coming back in patients with pancreatic cancer of the head of the pancreas.\"",[26,27],"Pancreatic Adenocarcinoma","Pancreatic Head Cancer",[29],"surgical oncology","NOT_YET_RECRUITING","2026-04-20",{"date":33,"type":34},"2026-04-23","ACTUAL",{"date":36,"type":20},"2026-09-01",{"date":38,"type":20},"2031-09-01",{"name":40,"class":41},"Assistance Publique - Hôpitaux de Paris","OTHER",23,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100633905","impact-of-intraoperative-ptcd-catheter-retention-versus-removal-on-postoperative-short-term-outcomes-after-pancreaticoduodenectomy-in-obstructive-jaundice-100633905","NCT07532759","Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pancreaticoduodenectomy in Obstructive Jaundice","Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pancreaticoduodenectomy in Obstructive Jaundice: An Exploratory Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 to 85 years\n* Patients with pancreatic head or periampullary tumors scheduled for pancreaticoduodenectomy\n* Presence of obstructive jaundice and completion of preoperative\n* percutaneous transhepatic cholangial drainage (PTCD)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* American Society of Anesthesiologists (ASA) physical status ≤ II\n* Able to understand the study and provide written informed consent\n\nExclusion Criteria:\n\n* Presence of distant metastasis or locally unresectable disease\n* Severe cardiac, renal, or pulmonary dysfunction that contraindicates surgery\n* Uncontrolled infection\n* Pregnancy or breastfeeding\n* History of major surgery within 4 weeks prior to enrollment\n* Poor compliance or inability to complete follow-up","85 Years",{"count":52,"type":20},100,[23],"Pancreaticoduodenectomy (PD) is a complex surgical procedure commonly performed for tumors of the pancreatic head and periampullary region. Many patients present with obstructive jaundice and undergo preoperative percutaneous transhepatic cholangial drainage (PTCD) to relieve biliary obstruction. However, there is currently no consensus on whether the PTCD catheter should be removed or retained during surgery.\n\nThis multicenter, prospective randomized controlled trial aims to compare two intraoperative strategies: removal versus retention of the PTCD catheter during PD. Participants will be randomly assigned to either group. The study will evaluate whether these different approaches influence postoperative outcomes, particularly major complications such as bile leak and severe postoperative morbidity within 90 days after surgery.\n\nIn addition to complications, the study will assess recovery after surgery, including return of gastrointestinal function, length of hospital stay, and quality of recovery, as well as laboratory indicators of liver function and inflammation.\n\nThe results of this study are expected to provide evidence to guide surgical decision-making regarding PTCD management during PD and to improve patient outcomes.",[56,27,57,58],"Obstructive Jaundice","Periampullary Neoplasms","Biliary Tract Neoplasms",[60,61,62,63,64,65,66],"Pancreaticoduodenectomy","PTCD","Biliary drainage","Biliary complications","Bile leak","Enhanced recovery","Randomized controlled trial","2026-04-09",{"date":69,"type":34},"2026-04-16",{"date":71,"type":20},"2026-05-01",{"date":73,"type":20},"2028-04-30",{"name":75,"class":41},"Xu'an Wang",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100610840","prognostic-outcomes-of-total-mesopancreas-excision-for-pancreatic-head-cancer-100610840","NCT07232810","Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer","Prognostic Outcomes of Total Mesopancreas Excision During Pancreaticoduodenectomy for Pancreatic Head Cancer","TMpE","Inclusion Criteria:\n\n* Age ≥18 years.\n* Patients scheduled to undergo pancreaticoduodenectomy with planned mesopancreatic excision.\n* Histologically confirmed PDAC of the pancreatic head (via endoscopic ultrasound-guided biopsy).\n* Resectable disease per National Comprehensive Cancer Network(NCCN) guidelines (no distant metastases, no arterial involvement \\>180°, venous involvement reconstructable).\n* Eastern Cooperative Oncology Group(ECOG) performance status 0-2.\n* Adequate organ function (e.g., bilirubin \\\u003C1.5x upper limit of normal(ULN), creatinine clearance \\>50 mL\u002Fmin).\n* Informed consent.\n\nExclusion Criteria:\n\n* Irresectable PDAC.\n* Distant metastases.\n* Periampullary tumors other than pancreatic adenocarcinoma\n* Prior neoadjuvant chemotherapy or radiotherapy (to isolate TMpE effect;may be amended for subgroups).\n* Active second malignancy.\n* Severe comorbidities precluding surgery (e.g., uncontrolled cardiac disease).\n* Pregnancy or lactation.\n* Patients who have received prior radiotherapy to the abdomen.\n* Patients unwilling or unable to provide informed consent.","80 Years",{"count":86,"type":20},90,[23],"Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to high recurrence rates after standard pancreaticoduodenectomy (PD). The concept of Total Mesopancreas Excision (TMpE), analogous to total mesorectal excision, aims to improve oncological outcomes by achieving higher R0 resection rates through the comprehensive removal of retroperitoneal connective tissue surrounding major peripancreatic vessels. This single arm prospective study will evaluate the prognostic outcomes, primarily Disease- Free Survival (DFS) at 24 months, of a standardized TMpE technique performed during pancreaticoduodenectomy for resectable pancreatic head cancer. Secondary objectives include assessing Overall Survival (OS), R0 resection rates, recurrence patterns, and perioperative outcomes in 90 consecutive patients.",[27,90],"Pancreatic Ductal Adenocarcinoma",[92,82,60,93,94,95],"Total Mesopancreas Excision","Pancreatic Cancer","DFS","R0 Resection","RECRUITING","2025-11-30",{"date":99,"type":34},"2025-12-02",{"date":101,"type":34},"2025-12-01",{"date":103,"type":20},"2027-12-20",{"name":105,"class":41},"Minia University",1]